Cellerant Therapeutics, Inc.

San Carlos, CA 94070

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $5.54MM
First Award Date 07/01/03
Most Recent Award Date 09/19/16

Key Personnel

Last Name Name Awards Contact
Fong Timothy C Fong 1
Scherer David C Scherer 1
Karsunky Holger Karsunky 3
Mandalam Ramkumar K Mandalam 2
Christensen Julie L. Christensen 2
Domen Adrianus G.W. Domen 1
JUNUTULA JAGATH JUNUTULA 1

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/19/16 - 09/18/18

The effectiveness of current AML treatments is abysmal yielding only an overall 5-year survival rate of ~25%, and it has been hypothesized that the treatment may be more durable if leukemic stem cells (LSC) are eliminated. IL1RAP is a compelling target because it is expressed on LSC in majority of AML patients, but not on healthy hematopoietic s...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 08/01/13 - 07/31/14

DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppress...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-08
Budget: 09/01/08 - 08/31/10

DESCRIPTION (provided by applicant): Our long term goal is to develop a universal cell-based therapy containing human myeloid progenitor cells to attenuate radiation-induced gastrointestinal or hematopoietic injury. Radiation (XRT) remains an important therapeutic modality in the treatment of malignancies. Injury to the gastrointestinal tract (G...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-08
Budget: 09/24/07 - 08/31/08

DESCRIPTION (provided by applicant): Our long term goal is to develop a universal cell-based therapy containing human myeloid progenitor cells to attenuate radiation-induced gastrointestinal or hematopoietic injury. Radiation (XRT) remains an important therapeutic modality in the treatment of malignancies. Injury to the gastrointestinal tract (G...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): Cellerant has successfully completed the Phase I feasibility research for the development of a neutrophil progenitor for the treatment of neutropenia e.g. during bone marrow transplantation, chemotherapy or after radiation exposure. In Phase I, the company demonstrated that human hematopoietic stem cells coul...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/15/06 - 07/31/07

DESCRIPTION (provided by applicant): Cellerant has successfully completed the Phase I feasibility research for the development of a neutrophil progenitor for the treatment of neutropenia e.g. during bone marrow transplantation, chemotherapy or after radiation exposure. In Phase I, the company demonstrated that human hematopoietic stem cells coul...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 08/01/05 - 01/31/07

DESCRIPTION (provided by applicant): Myeloablation is the damage that occurs to the bone marrow as a result of radiological or chemical exposure whether therapeutically administered or accidental, that, if left untreated, results in hematopoietic failure and death. Within the bone marrow it is the rare population of self-renewing hematopoietic s...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/05 - 06/14/06

DESCRIPTION (provided by applicant): Our long term goal is to develop a cell-based therapy containing human myeloid progenitor cells to enhance resistance to pathogens and recovery from infections after hematopoietic cell transplantation or chemotherapy. In our preclinical models, a single infusion of Common Myeloid Progenitors and Granulocyte/...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 08/15/04 - 07/31/05

DESCRIPTION (provided by applicant): Myeloablation is the damage that occurs to the bone marrow as a result of radiological or chemical exposure whether therapeutically administered or accidental, that, if left untreated, results in hematopoietic failure and death. Within the bone marrow it is the rare population of self-renewing hematopoietic s...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/03 - 06/30/05

DESCRIPTION (provided by applicant): Hematopoietic cell transplantation is a component of standard therapy for many malignant hematological diseases and is actively being investigated for use in treating non-hematological malignancies and autoimmune diseases, preventing the rejection of solid organ transplants and delivering gene therapy and imm...

Load More